AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading session ...

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

Photo: Uwe Anspach/dpa (Photo by Uwe Anspach/picture alliance via Getty Images) Barring the recent fall, ABBV stock has fared well, with 90% gains since early January 2021 — jumping from levels ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any industry ...

Even better, AbbVie isn't subject to crazy swings like many tech stocks and it is an excellent passive income stock. However, the dividend yield is at its lowest level in five years because of the ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

On Tuesday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $201.68 which represents a slight increase of $1.21 or 0.60% from the prior close of $200.47. The stock opened at $200.49 and ...

Shares of AbbVie Inc. ABBV tumbled 12.57% to $174.43 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.10% to 6,001.35 ...